AR124895A1 - Anticuerpos anti-cd30l y usos de estos - Google Patents
Anticuerpos anti-cd30l y usos de estosInfo
- Publication number
- AR124895A1 AR124895A1 ARP220100318A ARP220100318A AR124895A1 AR 124895 A1 AR124895 A1 AR 124895A1 AR P220100318 A ARP220100318 A AR P220100318A AR P220100318 A ARP220100318 A AR P220100318A AR 124895 A1 AR124895 A1 AR 124895A1
- Authority
- AR
- Argentina
- Prior art keywords
- cd30l
- seq
- acid sequence
- amino acid
- cdr
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 8
- 101100207070 Homo sapiens TNFSF8 gene Proteins 0.000 abstract 7
- 101100207071 Mus musculus Tnfsf8 gene Proteins 0.000 abstract 7
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 abstract 7
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 239000012634 fragment Substances 0.000 abstract 6
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 2
- 208000011231 Crohn disease Diseases 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
En el presente documento se describen anticuerpos anti-CD30L y composiciones farmacéuticas para el tratamiento de enfermedades y trastornos autoinmunitarios tales como la enfermedad inflamatoria intestinal (IBD), incluida la enfermedad de Crohn (CD) y la colitis ulcerosa (UC). Reivindicación 1: Un anticuerpo o fragmento de unión a antígeno de este que se une a CD30L, caracterizado porque el anticuerpo o fragmento de unión a antígeno de este comprende: (a) una CDR-H1 comprende la secuencia de aminoácidos establecida en una cualquiera de las SEQ ID Nº 100 a 139, 220 a 234, 465 a 489, 628 a 641, y 712 a 723; (b) una CDR-H2 que comprende la secuencia de aminoácidos de una cualquiera de las SEQ ID Nº 140 a 179, 235 a 249, 490 a 499, 513 a 527, 642 a 655 y 724 a 735; (c) una CDR-H3 que comprenden la secuencia de aminoácidos establecida en una cualquiera de las SEQ ID Nº 180 a 219, 250 a 264, 528 a 552, 656 a 669, y 736 a 743; (d) una CDR-L1 que comprende la secuencia de aminoácidos de una cualquiera de las SEQ ID Nº 300 a 339, 420 a 434, 553 a 577, 670 a 683, y 744 a 751; (d) CDR-L2 que comprende la secuencia de aminoácidos de una cualquiera de las SEQ ID Nº 340 a 379, 435 a 449, 578 a 602, 684 a 697 y 752 a 759; y/o (e) una CDR-L3 que comprende la secuencia de aminoácidos de una cualquiera de las SEQ ID Nº 380 a 419, 450 a 464, 603 a 627, 698 a 711 y 760 a 765. Reivindicación 6: Un anticuerpo o fragmento de unión a antígeno de este que se une a CD30L, caracterizado porque el anticuerpo o fragmento de unión a antígeno de este se une a un epítopo que comprende uno o más aminoácidos en CD30L seleccionados del grupo que consiste en K16, S21, R30, K48, R63 e Y64, donde los aminoácidos se numeran según la secuencia de aminoácidos de CD30L como se establece en la SEQ ID Nº 34. Reivindicación 8: Un anticuerpo o fragmento de unión a antígeno de este que se une a CD30L, caracterizado porque el anticuerpo o fragmento de unión a antígeno de este se une a un epítopo que comprende K16 en CD30L, donde los aminoácidos se numeran según la secuencia de aminoácidos de CD30L como se establece en la SEQ ID Nº 34.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150373P | 2021-02-17 | 2021-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124895A1 true AR124895A1 (es) | 2023-05-17 |
Family
ID=82931610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100318A AR124895A1 (es) | 2021-02-17 | 2022-02-16 | Anticuerpos anti-cd30l y usos de estos |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20240254246A1 (es) |
| EP (1) | EP4294840A1 (es) |
| JP (1) | JP7559257B2 (es) |
| KR (1) | KR20230157356A (es) |
| CN (2) | CN118047872A (es) |
| AR (1) | AR124895A1 (es) |
| AU (1) | AU2022224561A1 (es) |
| BR (1) | BR112023016445A2 (es) |
| CA (1) | CA3208060A1 (es) |
| CL (1) | CL2023002393A1 (es) |
| CO (1) | CO2023011962A2 (es) |
| CR (1) | CR20230445A (es) |
| EC (1) | ECSP23070234A (es) |
| IL (1) | IL305146A (es) |
| MX (1) | MX2023009621A (es) |
| PE (1) | PE20231680A1 (es) |
| TW (1) | TW202302637A (es) |
| WO (1) | WO2022177963A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023016445A2 (pt) | 2021-02-17 | 2023-12-12 | Dr Falk Pharma Gmbh | Anticorpos anti-cd30l e seus usos |
| WO2024026271A1 (en) * | 2022-07-25 | 2024-02-01 | Prometheus Biosciences, Inc. | Anti-cd30l antibodies, formulations therefor, and uses thereof |
| WO2024143497A1 (ja) * | 2022-12-28 | 2024-07-04 | 国立大学法人京都大学 | Ｃｄ１５３を標的とする医薬組成物 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| AU666388B2 (en) * | 1992-05-26 | 1996-02-08 | Immunex Corporation | Novel cytokine that binds CD30 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
| ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
| KR101155191B1 (ko) | 1999-01-15 | 2012-06-13 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| US6652854B2 (en) * | 2000-08-08 | 2003-11-25 | Immunex Corporation | Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| DK1667730T3 (da) | 2003-08-20 | 2013-09-23 | Univ Miami | Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom |
| CA2852954A1 (en) * | 2011-10-21 | 2013-04-25 | Nestec S.A. | Methods for improving inflammatory bowel disease diagnosis |
| RU2650800C2 (ru) * | 2012-04-27 | 2018-04-17 | Ново Нордиск А/С | Белки, связывающие антиген - лиганд cd30 человека |
| AU2016332900C1 (en) * | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| US20210208162A1 (en) | 2016-01-19 | 2021-07-08 | Global Down Syndrome Foundation | Down syndrome biomarkers and uses thereof |
| FI3774897T3 (fi) * | 2018-04-30 | 2023-11-03 | Cedars Sinai Medical Center | Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon |
| WO2020096046A1 (ja) | 2018-11-09 | 2020-05-14 | 国立大学法人大阪大学 | 老化関連ｔ細胞を標的とした糖代謝異常の予防または治療用ワクチン |
| BR112023016445A2 (pt) | 2021-02-17 | 2023-12-12 | Dr Falk Pharma Gmbh | Anticorpos anti-cd30l e seus usos |
-
2022
- 2022-02-16 BR BR112023016445A patent/BR112023016445A2/pt unknown
- 2022-02-16 PE PE2023002377A patent/PE20231680A1/es unknown
- 2022-02-16 CR CR20230445A patent/CR20230445A/es unknown
- 2022-02-16 US US18/546,955 patent/US20240254246A1/en active Pending
- 2022-02-16 IL IL305146A patent/IL305146A/en unknown
- 2022-02-16 AU AU2022224561A patent/AU2022224561A1/en active Pending
- 2022-02-16 EP EP22756817.7A patent/EP4294840A1/en active Pending
- 2022-02-16 CN CN202410189800.6A patent/CN118047872A/zh active Pending
- 2022-02-16 CN CN202280028982.8A patent/CN117255802A/zh active Pending
- 2022-02-16 WO PCT/US2022/016565 patent/WO2022177963A1/en active Application Filing
- 2022-02-16 CA CA3208060A patent/CA3208060A1/en active Pending
- 2022-02-16 TW TW111105667A patent/TW202302637A/zh unknown
- 2022-02-16 JP JP2023549602A patent/JP7559257B2/ja active Active
- 2022-02-16 MX MX2023009621A patent/MX2023009621A/es unknown
- 2022-02-16 KR KR1020237031681A patent/KR20230157356A/ko unknown
- 2022-02-16 AR ARP220100318A patent/AR124895A1/es unknown
- 2022-08-26 US US17/822,598 patent/US11866505B2/en active Active
-
2023
- 2023-08-14 CL CL2023002393A patent/CL2023002393A1/es unknown
- 2023-09-08 CO CONC2023/0011962A patent/CO2023011962A2/es unknown
- 2023-09-14 EC ECSENADI202370234A patent/ECSP23070234A/es unknown
- 2023-11-15 US US18/510,511 patent/US20240092923A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023016445A2 (pt) | 2023-12-12 |
| ECSP23070234A (es) | 2023-10-31 |
| MX2023009621A (es) | 2023-10-31 |
| US11866505B2 (en) | 2024-01-09 |
| CN118047872A (zh) | 2024-05-17 |
| EP4294840A1 (en) | 2023-12-27 |
| CL2023002393A1 (es) | 2024-03-22 |
| CR20230445A (es) | 2023-11-14 |
| PE20231680A1 (es) | 2023-10-19 |
| US20230060624A1 (en) | 2023-03-02 |
| US20240092923A1 (en) | 2024-03-21 |
| WO2022177963A1 (en) | 2022-08-25 |
| AU2022224561A1 (en) | 2023-09-28 |
| CO2023011962A2 (es) | 2023-09-29 |
| KR20230157356A (ko) | 2023-11-16 |
| JP2024509746A (ja) | 2024-03-05 |
| CN117255802A (zh) | 2023-12-19 |
| AU2022224561A9 (en) | 2023-10-05 |
| US20240254246A1 (en) | 2024-08-01 |
| IL305146A (en) | 2023-10-01 |
| CA3208060A1 (en) | 2022-08-25 |
| TW202302637A (zh) | 2023-01-16 |
| JP7559257B2 (ja) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124895A1 (es) | Anticuerpos anti-cd30l y usos de estos | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| RU2019118359A (ru) | Антитело к cd73 человека | |
| HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
| HRP20201939T1 (hr) | Anti-c10orf54 antitijela i njihova primjena | |
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| PE20211605A1 (es) | ANTICUERPOS ANTI-avß8 Y COMPOSICIONES Y USOS DE LOS MISMOS | |
| JP2010022372A5 (es) | ||
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| PE20121646A1 (es) | Anticuerpo anti-tslp modificado por tecnicas de ingeneria genetica | |
| SG184473A1 (en) | Tnf-alpha binding proteins | |
| JP2016512551A5 (es) | ||
| RU2011115559A (ru) | Антитела к cxcr4 и их применение для лечения рака | |
| AR080243A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
| JP2012532851A5 (es) | ||
| PE20240142A1 (es) | Anticuerpos inhibidores via del factor tisular y usos de los mismos | |
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| AR110659A1 (es) | Proteínas de unión a antígenos anti-neuropilin y método para su uso | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos | |
| US12098197B2 (en) | Polypeptides comprising immunoglobulin chain variable domains which bind to interleukin-6 receptor (IL-6R) and methods of use thereof to treat autoimmune and inflammatory diseases | |
| CN108424449A (zh) | 针对艰难梭菌的主要外毒素TcdA和TcdB的中和抗体 | |
| PE20121645A1 (es) | Composiciones y metodos para tratar trastornos inflamatorios | |
| PE20220279A1 (es) | Inhibidores especificos del complejo de ltbp de tgf beta y usos de los mismos | |
| RU2013110844A (ru) | АНТИТЕЛА ПРОТИВ IL-1β И IL-18, ИСПОЛЬЗУЕМЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ | |
| IL275223B2 (en) | Anti-alpha-synuclein antibodies |